364 related articles for article (PubMed ID: 16513111)
1. Pathogenesis, animal models and therapeutics in spinal and bulbar muscular atrophy (SBMA).
Katsuno M; Adachi H; Waza M; Banno H; Suzuki K; Tanaka F; Doyu M; Sobue G
Exp Neurol; 2006 Jul; 200(1):8-18. PubMed ID: 16513111
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis-targeting therapeutics for spinal and bulbar muscular atrophy (SBMA).
Suzuki K; Kastuno M; Banno H; Sobue G
Neuropathology; 2009 Aug; 29(4):509-16. PubMed ID: 19486304
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.
Adachi H; Waza M; Katsuno M; Tanaka F; Doyu M; Sobue G
Neuropathol Appl Neurobiol; 2007 Apr; 33(2):135-51. PubMed ID: 17359355
[TBL] [Abstract][Full Text] [Related]
4. [Animal models of neurodegenerative diseases on the road to disease-modifying therapy: spinal and bulbar muscular atrophy].
Sobue G
Rinsho Shinkeigaku; 2007 Nov; 47(11):941-3. PubMed ID: 18210842
[TBL] [Abstract][Full Text] [Related]
5. [Paradigm shift in clinical trials for neurodegenerative diseases].
Katsuno M; Banno H; Suzuki K; Takeuchi Y; Sobue G
Brain Nerve; 2007 Apr; 59(4):367-74. PubMed ID: 17447523
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA).
Katsuno M; Tanaka F; Adachi H; Banno H; Suzuki K; Watanabe H; Sobue G
Prog Neurobiol; 2012 Dec; 99(3):246-56. PubMed ID: 22609045
[TBL] [Abstract][Full Text] [Related]
7. Loss of endogenous androgen receptor protein accelerates motor neuron degeneration and accentuates androgen insensitivity in a mouse model of X-linked spinal and bulbar muscular atrophy.
Thomas PS; Fraley GS; Damian V; Woodke LB; Zapata F; Sopher BL; Plymate SR; La Spada AR
Hum Mol Genet; 2006 Jul; 15(14):2225-38. PubMed ID: 16772330
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA).
Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
Cell Tissue Res; 2012 Jul; 349(1):313-20. PubMed ID: 22476656
[TBL] [Abstract][Full Text] [Related]
9. Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker.
Banno H; Adachi H; Katsuno M; Suzuki K; Atsuta N; Watanabe H; Tanaka F; Doyu M; Sobue G
Ann Neurol; 2006 Mar; 59(3):520-6. PubMed ID: 16358333
[TBL] [Abstract][Full Text] [Related]
10. [Study of androgen receptor expression and neuronal vulnerability in X-linked spinal and bulbar muscular atrophy].
Matsuura T
Hokkaido Igaku Zasshi; 1996 Nov; 71(6):785-99. PubMed ID: 8996845
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.
Banno H; Katsuno M; Suzuki K; Takeuchi Y; Kawashima M; Suga N; Takamori M; Ito M; Nakamura T; Matsuo K; Yamada S; Oki Y; Adachi H; Minamiyama M; Waza M; Atsuta N; Watanabe H; Fujimoto Y; Nakashima T; Tanaka F; Doyu M; Sobue G
Ann Neurol; 2009 Feb; 65(2):140-50. PubMed ID: 19259967
[TBL] [Abstract][Full Text] [Related]
12. [Molecular pathogenesis of motor neuron diseases].
Sobue G
Nihon Shinkei Seishin Yakurigaku Zasshi; 2001 Feb; 21(1):21-25. PubMed ID: 11400322
[TBL] [Abstract][Full Text] [Related]
13. [Disease-modifying therapy for spinal and bulbar muscular atrophy (SBMA)].
Suzuki K; Banno H; Katsuno M; Adachi H; Tanaka F; Sobue G
Brain Nerve; 2012 Mar; 64(3):237-44. PubMed ID: 22402717
[TBL] [Abstract][Full Text] [Related]
14. Spinal and bulbar muscular atrophy: ligand-dependent pathogenesis and therapeutic perspectives.
Katsuno M; Adachi H; Tanaka F; Sobue G
J Mol Med (Berl); 2004 May; 82(5):298-307. PubMed ID: 15133611
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy.
Katsuno M; Banno H; Suzuki K; Adachi H; Tanaka F; Sobue G
Arch Neurol; 2012 Apr; 69(4):436-40. PubMed ID: 22158719
[TBL] [Abstract][Full Text] [Related]
16. Neuropathology and therapeutic intervention in spinal and bulbar muscular atrophy.
Banno H; Katsuno M; Suzuki K; Tanaka F; Sobue G
Int J Mol Sci; 2009 Mar; 10(3):1000-12. PubMed ID: 19399234
[TBL] [Abstract][Full Text] [Related]
17. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse.
Tokui K; Adachi H; Waza M; Katsuno M; Minamiyama M; Doi H; Tanaka K; Hamazaki J; Murata S; Tanaka F; Sobue G
Hum Mol Genet; 2009 Mar; 18(5):898-910. PubMed ID: 19066230
[TBL] [Abstract][Full Text] [Related]
18. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA.
Suzuki K; Katsuno M; Banno H; Takeuchi Y; Atsuta N; Ito M; Watanabe H; Yamashita F; Hori N; Nakamura T; Hirayama M; Tanaka F; Sobue G
Brain; 2008 Jan; 131(Pt 1):229-39. PubMed ID: 18056738
[TBL] [Abstract][Full Text] [Related]
19. Transgenic mouse models of spinal and bulbar muscular atrophy (SBMA).
Katsuno M; Adachi H; Inukai A; Sobue G
Cytogenet Genome Res; 2003; 100(1-4):243-51. PubMed ID: 14526186
[TBL] [Abstract][Full Text] [Related]
20. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.
Waza M; Adachi H; Katsuno M; Minamiyama M; Sang C; Tanaka F; Inukai A; Doyu M; Sobue G
Nat Med; 2005 Oct; 11(10):1088-95. PubMed ID: 16155577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
